Clinical Trials Browser

Active not recruiting × Leuprolide × Genitourinary × Clear all

NCT04484818 2026-03-02

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05320406 2026-02-12

REVELUTION

Phase 2 Active not recruiting

94 enrolled 13 charts

Prostatic Neoplasms

NCT06627530 2026-02-11

COAction

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT03902951 2026-02-05

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04455750 2026-02-05

CASPAR

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04126070 2026-01-22

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Phase 2 Active not recruiting

Hormone Sensitive Prostate Cancer

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

Phase 2 Active not recruiting

188 enrolled 25 charts

Prostatic Neoplasms

NCT00329043 2025-12-26

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04181203 2025-07-30

CARLHA-2

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT04194554 2025-06-04

ASCLEPIuS

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Phase 3 Active not recruiting

1,792 enrolled 27 charts

Prostatic Neoplasms

NCT00544830 2025-05-07

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2 Active not recruiting

29 enrolled 12 charts

PSA Level Greater Than Two

NCT03703778 2025-05-06

READT

Active not recruiting

Prostatic Neoplasms

NCT03361735 2025-05-02

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostate Adenocarcinoma

NCT02346253 2025-04-03

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Phase NA Active not recruiting

Prostatic Neoplasms

NCT02685397 2024-12-04

PCS IX

Phase 2/3 Active not recruiting

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT00430183 2023-02-09

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Phase 3 Active not recruiting

788 enrolled 10 charts

Prostatic Neoplasms